Accueil Our therapeutic areas
Improving the health of millions of people around the world
2.5 million patients treated with our medicines in 2023
Juvisé Pharmaceuticals is committed to helping patients with relapsing-remitting multiple sclerosis.
Chronic depression, anxiety disorders, bipolar disorders, schizophrenia.
Since 2022, Juvisé Pharmaceuticals has been engaged in the fight against H. pylori infection, one of the most common chronic infections, affecting around 50% of the world’s population.
JUV-FRA-202408-0213, 09/2024